PDE5 INHIBITORS
Not only sildenafil citrate (Viagra) but all of the other currently available phosphodiesterase 5 inhibitors used for erectile dysfunction may increase the risk of central serous chorioretinopathy (CSC). Two case studies of patients who developed taking PDE5 inhibitors (vardenafil and tadalafil) for erectile dysfunction showed that the condition resolved once they discontinued use of the agents but reappeared when they resumed using it and once again resolved when they stopped using it the second time. The authors of the study note that there have been previous reports of CSC in patients taking sildenafil citrate. Previous studies have also indicated a link between the use of PDE5 inhibitors and other ocular side effects, including lid oedema, hyposphagma, photophobia, mydriasis, dyschromatopsia, and nonarteritic anterior ischemic optic neuropathy. The evidence suggests CSC may be another rare PDE5 inhibitor class-specific side effect, the study’s authors said
(Aliferis et al, Ophthalmogica 2012; 227:85-89)
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.